{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MATCHING+PLACEBO&page=8",
    "query": {
      "intervention": "MATCHING PLACEBO",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 7020,
    "total_pages": 702,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MATCHING+PLACEBO&page=9&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MATCHING+PLACEBO&page=7&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-26T14:54:01.616Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02130193",
      "title": "Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Danirixin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "40 Years to 70 Years"
      },
      "enrollment_count": 102,
      "start_date": "2014-02-13",
      "completion_date": "2016-08-29",
      "has_results": true,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-10-26T14:54:01.616Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Denver, Colorado • Iowa City, Iowa + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Oaks",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02130193"
    },
    {
      "nct_id": "NCT02787304",
      "title": "Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Alcoholic Steatohepatitis"
      ],
      "interventions": [
        {
          "name": "SHP626",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mirum Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 197,
      "start_date": "2016-10-24",
      "completion_date": "2018-07-27",
      "has_results": true,
      "last_update_posted_date": "2019-11-25",
      "last_synced_at": "2026-10-26T14:54:01.616Z",
      "location_count": 49,
      "location_summary": "Coronado, California • Fresno, California • Los Angeles, California + 42 more",
      "locations": [
        {
          "city": "Coronado",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Rialto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02787304"
    },
    {
      "nct_id": "NCT02322333",
      "title": "MLD10 in the Prevention of Migraine in Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Migraine"
      ],
      "interventions": [
        {
          "name": "MLD10",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pharmalyte Solutions LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 157,
      "start_date": "2015-03",
      "completion_date": "2017-06",
      "has_results": true,
      "last_update_posted_date": "2020-10-09",
      "last_synced_at": "2026-10-26T14:54:01.616Z",
      "location_count": 9,
      "location_summary": "Carlsbad, California • San Francisco, California • Oviedo, Florida + 6 more",
      "locations": [
        {
          "city": "Carlsbad",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Oviedo",
          "state": "Florida"
        },
        {
          "city": "Snellville",
          "state": "Georgia"
        },
        {
          "city": "Kalamazoo",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02322333"
    },
    {
      "nct_id": "NCT00763815",
      "title": "GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus Type 2"
      ],
      "interventions": [
        {
          "name": "Lixisenatide (AVE0010)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Pen auto-injector",
          "type": "DEVICE"
        },
        {
          "name": "Pioglitazone",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 484,
      "start_date": "2008-09",
      "completion_date": "2011-06",
      "has_results": true,
      "last_update_posted_date": "2016-11-28",
      "last_synced_at": "2026-10-26T14:54:01.616Z",
      "location_count": 85,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 72 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00763815"
    },
    {
      "nct_id": "NCT00933608",
      "title": "Effects of Memantine on Magnetic Resonance (MR) Spectroscopy in Subjects at Risk for Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "memantine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "55 Years to 90 Years"
      },
      "enrollment_count": 17,
      "start_date": "2009-07",
      "completion_date": "2011-09",
      "has_results": true,
      "last_update_posted_date": "2014-10-21",
      "last_synced_at": "2026-10-26T14:54:01.616Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00933608"
    },
    {
      "nct_id": "NCT03542110",
      "title": "The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts (ASAP-SVG) Pilot Trial",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Saphenous Vein Graft Atherosclerosis"
      ],
      "interventions": [
        {
          "name": "Alirocumab 150 MG/ML subcutaneous injection",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo subcutaneous injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Minneapolis Heart Institute Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2018-08-04",
      "completion_date": "2020-07-31",
      "has_results": false,
      "last_update_posted_date": "2021-09-16",
      "last_synced_at": "2026-10-26T14:54:01.616Z",
      "location_count": 4,
      "location_summary": "San Francisco, California • Atlanta, Georgia • Minneapolis, Minnesota + 1 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03542110"
    },
    {
      "nct_id": "NCT06789913",
      "title": "A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "PIK3CA-Related Overgrowth Spectrum (PROS)",
        "Lymphatic Malformations",
        "Vascular Malformations",
        "PIK3CA Mutation",
        "CLOVES Syndrome",
        "Klippel Trenaunay Syndrome",
        "Megalencephaly-capillary Malformation Polymicrogyria Syndrome (MCAP)",
        "Vascular Anomalies"
      ],
      "interventions": [
        {
          "name": "RLY-2608",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Relay Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 277,
      "start_date": "2025-06-13",
      "completion_date": "2031-10",
      "has_results": false,
      "last_update_posted_date": "2026-08-25",
      "last_synced_at": "2026-10-26T14:54:01.616Z",
      "location_count": 22,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06789913"
    },
    {
      "nct_id": "NCT01122680",
      "title": "Efficacy and Safety of 3 Doses of Tiotropium Compared to Placebo in Adolescents (12 to 17 Yrs) With Moderate Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "tiotropium bromide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 105,
      "start_date": "2010-05",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2014-05-16",
      "last_synced_at": "2026-10-26T14:54:01.616Z",
      "location_count": 5,
      "location_summary": "Denver, Colorado • Columbia, Missouri • Warrensburg, Missouri + 2 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Columbia",
          "state": "Missouri"
        },
        {
          "city": "Warrensburg",
          "state": "Missouri"
        },
        {
          "city": "Boys Town",
          "state": "Nebraska"
        },
        {
          "city": "Canton",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01122680"
    },
    {
      "nct_id": "NCT03374488",
      "title": "Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "UC (Urothelial Cancer)"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Epacadostat",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 84,
      "start_date": "2017-12-22",
      "completion_date": "2020-07-23",
      "has_results": true,
      "last_update_posted_date": "2025-08-22",
      "last_synced_at": "2026-10-26T14:54:01.616Z",
      "location_count": 24,
      "location_summary": "Chandler, Arizona • Orange, California • San Francisco, California + 19 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03374488"
    },
    {
      "nct_id": "NCT00487825",
      "title": "Safety and Efficacy of Intravenous ACZ885 and Oral Methotrexate Therapy in Patients With Early Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Canakinumab (investigational)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate (MTX)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 78,
      "start_date": "2007-03",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2012-08-01",
      "last_synced_at": "2026-10-26T14:54:01.616Z",
      "location_count": 17,
      "location_summary": "Huntsville, Alabama • Tuscaloosa, Alabama • Paradise Valley, Arizona + 14 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Paradise Valley",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "South Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00487825"
    }
  ]
}